Patents Examined by Noble Jarrell
  • Compounds with super-aspirin effects
    Patent number: 9670223
    Abstract: A compound having the structural formula (I) and pharmaceutically acceptable salt and/or hydrates thereof, (I) wherein Y is an arylester or an C1-C8 alkylaryl ester, selected from the group consisting of: benzene, toluene, xylene, benzoic acid, benzoate, nicotinate, isonicotinate and halobenzene, which can be unsubstituted or substituted with at least one nitric oxide releasing group; and/or at least one of hydroxide, —Cl, —Br, a C1-C8 alkyl, benzyl, a C1-C8 alkoxy, benzyloxy, —NHC(O)R, —NH2, —NO2, —ONO2, —(CH2)nONO2, —OC(O)[(CH2)m], cyclic ONO2, —OCOArONO2, —OCOAr(CH2)nONO2 or a C1-C5 haloalkyl ester, wherein R is a C1-C8 alkyl or a C1-C8 alkoxy group, n=1-8 and m=3-10, to produce a super-aspirin effect.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: June 6, 2017
    Assignee: SOLVOTRIN THERAPEUTICS LTD.
    Inventors: John Francis Gilmer, Mark Ledwidge, Pat O'Flynn, Shona Harmon, Marek Radomski, Carlos Medina Martin
  • Substituted 4-cyan-3-(pyridyl)-4-phenylbutanoates, method for the production thereof and uses as herbicides and plant growth regulators
    Patent number: 9661848
    Abstract: 4-Cyano-3-(pyridyl)-4-phenylbutanoates, processes for their preparation and their use as herbicides and plant growth regulars Compounds of the formula (I) or salts thereof in which R1, (R2)n and Q are as defined in Claim 1 are suitable as herbicides for the control of harmful plants or as plant growth regulators. The compounds can be prepared by the process claimed.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: May 30, 2017
    Assignee: BAYER CROPSCIENCE AG
    Inventors: Harald Jakobi, Marc Mosrin, Hansjoerg Dietrich, Elmar Gatzweiler, Christopher Hugh Rosinger, Dirk Schmutzler
  • 3-aryl-2-((arylamino)methyl)quinazolin-4-(3H)-ones
    Patent number: 9662331
    Abstract: The invention relates to novel quinazolinone compounds and their use as inhibitors of PI3 kinases, for example, PI3K?, for treating and/or preventing diseases, disorder, and conditions associated with modulating PI3 kinase activity. Novel 3 -aryl-2-((arylamino)methyl)quinazolin-4(3H)-one derivatives and pharmaceutically acceptable salts or solvates thereof and their use for the treatment or prevention of diseases, disorders, and conditions associated with the activity of one or more PI3 kinase, such as PI3K?, are disclosed.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: May 30, 2017
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Ben C. Askew, Takeru Furuya
  • Salts of heterocyclic modulators of HIF activity for treatment of disease
    Patent number: 9663504
    Abstract: The present disclosure relates to salts of heterocyclic compounds and methods that inhibit HIF pathway activity. The compounds are designed to treat or prevent cancer and other hypoxia-mediated diseases.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: May 30, 2017
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip Jones, Maria Emilia Di Francesco, Timothy McAfoos
  • Inhibitors of human immunodeficiency virus replication
    Patent number: 9663536
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. Formule (I).
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: May 30, 2017
    Assignee: ViiV HEALTHCARE UK (NO.5) LIMITED
    Inventors: B. Narasimhulu Naidu, Manoj Patel, Kevin Peese, Zhongyu Wang
  • Chemical compounds
    Patent number: 9657008
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 and R2 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: May 23, 2017
    Assignee: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Benedicte Delouvrie, Craig Steven Harris, Christine Marie Paul Lambert-Van der Brempt, Gilles Ouvry, Gary Patrick Reid, David Berry, Gary Peter Tomkinson
  • Synthesis of 2-carboxamide cycloamino urea derivatives
    Patent number: 9650373
    Abstract: Provided herein are processes useful for the preparation of 2-carboxamide cycloamino urea derivatives of formula (X), and useful intermediates therefore, at internal temperatures such as less than about ?5° C. to about ?15° C. and using solvents such as tetrahydrofuran, bases such as amines, and the like.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: May 16, 2017
    Assignee: Novartis AG
    Inventors: Bernhard Erb, Isabelle Sylvie Gallou, Florian Karl Kleinbeck
  • Imidazo(4,5-) pyridin-2-yl amides as K7 channel activators
    Patent number: 9650376
    Abstract: Compounds represented by formula 1 can be potent and/or partially selective for the Kv7.2/7.3 heteromultimer. They may be useful in treating disorders related to seizures, pain, neurotransmitter release, etc.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: May 16, 2017
    Assignee: KNOPP BIOSCIENCES LLC
    Inventors: Lynn Resnick, George T. Topalov, Steven A. Boyd, Justin K. Belardi, Charles A. Flentge, James S. Hale, Scott S. Harried, David A. Mareska, Kai Zhang, Charles R. Heap, Mark Hadden, Wenge Cui, Hélène Decornez, Shuang Liu
  • Antibacterial compounds and methods for use
    Patent number: 9650395
    Abstract: The present description relates to compounds and forms and pharmaceutical compositions thereof and methods for use thereof to treat or ameliorate bacterial infections caused by wild-type and multi-drug resistant Gram-negative and Gram-positive pathogens.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: May 16, 2017
    Assignee: PTC Therapeutics, Inc.
    Inventors: Arthur Branstrom, Vara Prasad Venkata Nagendra Josyula, Michael Andrew Arnold, Aleksey I. Gerasyuto, Gary Karp, Jiashi Wang, Tamil Arasu, John David Baird, Wu Du, Olya Ginzburg, Yi Jin Kim Gorske, Jana Narasimhan, Srinivasa Peddi, Hongyan Qi, Sean Wesley Smith, Anthony Allan Turpoff, Richard Gerald Wilde, Tianle Yang, Nanjing Zhang, Xiaoyan Zhang
  • 2-pyridyloxy-3-nitrile-4-substituted orexin receptor antagonists
    Patent number: 9643955
    Abstract: The present invention is directed to 2-pyridyloxy-3-nitrile-4-substituted compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-3-nitrile-4-substituted compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: May 9, 2017
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Scott D. Kuduk, Jason W. Skudlarek
  • Boronic acid derivatives and therapeutic uses thereof
    Patent number: 9642869
    Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents. Other embodiments relate to pharmaceutical compositions containing boronic acid derivatives and additional excipient such as meglumine.
    Type: Grant
    Filed: January 2, 2014
    Date of Patent: May 9, 2017
    Assignee: Rempex Pharmaceuticals, Inc.
    Inventors: Raja K. Reddy, Tomasz Glinka, Maxim Totrov, Scott Hecker
  • Procaspase activating compounds
    Patent number: 9643960
    Abstract: Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed that have lower neurotoxicity effects than other compounds.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: May 9, 2017
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Paul J. Hergenrother, Quinn Patrick Peterson, Danny Chung Hsu, Diana C. West, Timothy M. Fan, Chris J. Novotny
  • Cross-linkers for hydrogels, hydrogels including these cross-linkers and applications thereof
    Patent number: 9644076
    Abstract: The present invention relates to novel cross-linkers for hydrogels, in particular for hyaluronan hydrogels, corresponding hydrogels including said cross-linkers and various applications thereof. The cross linker of the invention is a bi- or multifunctional cross-linker comprising or consisting of an aromatic or heteroaromatic ring system with 3-6 C atoms which is coupled via functional groups on at least 2 ring positions with at least 2 terminal groups capable to form a covalent bond with thiol or amino groups, in particular with thiol groups in a thiol-en reaction. The cross-linker may be charged or uncharged. In a specific embodiment, the terminal groups are coupled to carboxy groups of the aromatic or heteroaromatic ring system via an ester or amide bond.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: May 9, 2017
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschafen e. V.
    Inventors: Heike Boehm, Valentin Hagel, Tabea Mundinger, Isabell Nuss, Seraphine Valeska Wegner, Sabine Laschat, Markus Manfred Mateescu
  • Liquid crystal compound having 2, 6-difluorophenyl ether structure and liquid crystal composition thereof
    Patent number: 9637466
    Abstract: The present invention relates to a compound having 2,6-difluorophenyl ether structure and useful as an organic electronic material and a medicine/agrochemical, particularly a material for liquid crystal display devices, and also relates to an effective method for producing the same. The present invention provides a compound represented by general formula (1) and also provides a liquid crystal composition containing the compound and a liquid crystal display device using the liquid crystal composition. A liquid crystal composition exhibiting low viscosity and a liquid crystal phase within a wide temperature range can be produced by using the compound represented by the general formula (1) as a component of the liquid crystal composition. Thus, the compound is very useful as a constituent component of a liquid crystal composition for a liquid crystal display device required to have, fast response.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: May 2, 2017
    Assignee: DIC CORPORATION
    Inventors: Kenta Tojo, Tetsuo Kusumoto
  • Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts
    Patent number: 9636344
    Abstract: The present invention relates to 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride salt of formula (II): or a tautomer, solvate or hydrate thereof; and to its use for the treatment of non-Hodgkin's lymphoma.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: May 2, 2017
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Jan-Georg Peters, Hans-Christian Militzer, Hartwig Müller
  • Heteroaryl compounds as 5-HTreceptor ligands
    Patent number: 9636335
    Abstract: The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts. The compounds of formula (I) are useful in the treatment of various disorders that are related to 5-HT4 receptors.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: May 2, 2017
    Assignee: SUVEN LIFE SCIENCES LIMITED
    Inventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Suresh Yarlagadda, Srinivasa Rao Ravella, Anil Karbhari Shinde, Ramasastri Kambhampati, Praveen Kumar Roayapalley, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Sriramachandra Murthy Patnala, Jyothsna Ravula, Venkateswarlu Jasti
  • Compositions and methods for treating psoriasis
    Patent number: 9636321
    Abstract: Novel isohexides and pharmaceutical compositions containing the same as well as methods of using the same in the treatment of psoriasis.
    Type: Grant
    Filed: March 27, 2016
    Date of Patent: May 2, 2017
    Assignee: SYMBIONYX PHARMACEUTICALS INC.
    Inventors: Ratan K Chaudhuri, Krys Bojanowski
  • Acrylamide derivatives as antimalarial agents
    Patent number: 9637473
    Abstract: The invention relates to novel acrylamide derivatives of the formula I wherein R1, R2, R3, X, and ring A are as defined in the description, and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including pharmaceutical compositions containing those compounds and their use as medicaments for the treatment or prevention of protozoal infections, such as especially malaria.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 2, 2017
    Assignee: ACTELION PHARMACEUTICALS LTD.
    Inventors: Hamed Aissaoui, Christoph Boss, Claire-Lise Ciana, Thierry Kimmerlin, Romain Siegrist
  • Compounds and methods for detection of enzymes that remove formyl, succinyl, methyl succinyl or myristoyl groups from ?-amino lysine moieties
    Patent number: 9637773
    Abstract: Provided is a compound that comprises the structure: where SIG is a signaling molecule and R3 is a formyl, a succinyl, a methyl succinyl, or a myristoyl. Also provided is a kit is provided that comprises the above compound, with instructions for determining the presence of the enzyme. Additionally, a method is provided for determining whether a sample has an enzyme that removes a succinyl, a methyl succinyl, a formyl, or a myristoyl moiety from an ?-amino of a lysine. Also provided is a method of determining whether a molecule inhibits an enzyme that removes a succinyl, a methyl succinyl, a formyl, or a myristoyl moiety from an ?-amino of a lysine.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: May 2, 2017
    Assignee: Enzo Life Sciences, Inc.
    Inventors: Konrad T. Howitz, Zhongda Zhang, Anne Kisielewski, Elizabeth Dale, Wayne Forrest Patton
  • Enzyme and receptor modulation using covalent conjugates of alpha,alpha-disubstituted glycine esters
    Patent number: 9636409
    Abstract: Covalent conjugates of an ?,?-disubstituted glycine ester and a modulator of the activity of a target intracellular enzyme or receptor, wherein the ester group of the conjugate is hydrolysable by one or more intracellular carboxylesterase enzymes to the corresponding acid and the ?,?-disubstituted glycine ester is conjugated to the modulator at a position remote from the binding interface between the inhibitor and the target enzyme or receptor pass into cells and the active acid hydrolysis product accumulates within the cells, as in the following compound:
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: May 2, 2017
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Alan Hastings Drummond, Alan Hornsby Davidson, David Festus Charles Moffat, Alastair David Graham Donald, Stephen John Davies